

Results

Table 12: Age of the studied cases.

	Asthma Diabetes		Renal	ANOVA		
	7 Istiiiia	Diabetes	Renar	F. test	P-value	
Range	5-12	5-16	8-17	17.325	0.009	
Mean + SD	8 <u>+</u> 1.947	10.95 <u>+</u> 3.47	14.50 <u>+</u> 2.58	11,020	0.007	

Table 13: Demographic data of the studied cases in different chronic diseases and control groups.

		Asthma	Diabetes	Renal	Control	\mathbf{X}^2	P- value
	Male	9	11	12	10		
Sex	Maie	45%	55%	60%	50%	0.141	0.934
Sex	Female	11	9	8	10	0.141	0.934
	remale	55%	45%	40%	50%		
Casia	Low	17	16	19	12		
Socio-	Low	85%	80%	95%	60%	1 225	0.019*
economic status	Moderate	3	4	1	8	4.235	
Status		15%	20%	5%	40%		
	Never	0	1	1	0		
	Joined school	0%	5%	5%	0%		
Education	Diggontinus	1	2	7	0	5.302	0.028*
level	Discontinue	5%	10%	35%	0%		
	Still at	18	17	12	20		
	School	90%	85%	60%	100%		

This table shows that incidence of low social class is significant and most of the patients are still in the education.





Table 14: Incidence of complications in each chronic disease

		Asthma	Diabetes	Renal	Total
(+ve)	N	2	10	18	30
(146)	%	10%	50%	90%	50%
(-ve)	N	18	10	2	30
	%	90%	50%	10%	50%
Total	N	20	20	20	60
Total	%	100%	100%	100%	100%
	\mathbf{X}^2		21.3	369	
Chi-square	P-		< 0.0	02*	
	value		νο.ο	02	

This table shows highly significant difference [P-value<0.002] between the different diseases as regard to complications; as 18 (90%) of renal patients have complications, then 10(50%) of diabetic patients have complications, the least percentage of complications incidence was in asthmatic patients (10%=2 patients).




Fig.(5): Incidence of complications in different chronic diseases in the study.





Table 15: Compliance to treatment in the studied cases in each chronic disease.

Complia	nce	Asthma	Diabetes	Renal	Total
(170)	N	18	18	17	53
(+ve)	%	90%	90%	85%	88.33%
(710)	N	2	2	3	7
(-ve)	%	10%	10%	15%	11.67%
Total	N	20	20	20	60
Total	%	100%	100%		
	\mathbf{X}^2		28.3	325	
Chi-square	P- value		<0.0	01*	

This table shows high significant difference [P-value<0.001], as majority of patients were compliant to treatment.

Table16: Duration of each chronic disease in the studied cases.

		Asthma	Diabetes	Renal	Total
-1woon	N	0	2	1	3
<1year	%	0%	10%	5%	5%
> 1woon	N	20	18	19	57
>1year	%	100%	90%	95%	95%
Total	N	20	20	20	60
1 Otai	%	100%	100%	100%	100%
Chi-square	\mathbf{X}^2		3.6	28	
Cin-square	P-value		0.3	63	

The table shows that majority of study cases were more than one year.





Table 17: Comparison of anxiety grades between patients of different chronic diseases and control groups.

A			Groups								
Anxiet	L y	Asthma	Diabetes	Renal	Control	Total					
M:1.1	N	8	9	5	13	35					
Mild	%	40%	45%	25%	65%	43.75%					
Moderate	N	10	8	10	7	35					
Moderate	%	50%	40%	50%	35%	43.75%					
Severe	N	2	2 3 5 0			10					
Severe	%	10%	0% 15% 25% 0%								
Total	N	20	20	20	20	80					
Total	%	100%	100%	100%	100%	100%					
	² X			13.692							
Chi-square	P-			0.028*							
	value			U.U ∠ ð"							

The table shows significant increase in anxiety between the chronic diseased patients than healthy children with P-value=0.028.

.Table 18: Comparison of depression grades between patients of different chronic diseases and control groups.

Donwood	ion		8	Groups		
Depress	1011	Asthma	Diabetes	Renal	Control	Total
No	N	13	15	4	18	50
NO	%	65%	75%	20%	90%	62.50%
Mild	N	5	3	11	2	21
Willu	%	25%	15%	55%	10%	26.25%
Moderate	N	2	2	3	0	7
Moderate	%	10%	10%	15%	0%	8.75%
Severe	N	0	2			
Severe	%	0%	0%	10%	0%	2.50%
Total	N	20	20	20	20	80
Total	%	100%	100%	100%	100%	100%
	² X			26.720		
Chi-square	P- value			0.002*		

The table shows high significant increase in depression between the chronic diseased patients than healthy children with P-value=0.002.





Table19: Comparison of anxiety between patients in different chronic diseases and control groups as regard to sex.

			Sex								
Groups	Anxiety	N	Male	F	emale	emale T		Chi-	square		
Groups	TillAlety	N	%	N	%	N	%	X^2	P- value		
	Mild	5	25%	3	15%	8	40%				
Asthma	Moderate	4	20%	6	30%	10	50%	2.925	0.045*		
	Severe	0	0%	2	10%	2	10%				
	Mild	8	40%	1	5%	9	45%		0.541		
Diabetes	Moderate	3	15%	5	25%	8	40%	1.147			
	Severe	0	0%	3	15%	3	15%				
	Mild	5	25%	0	0%	5	25%				
Renal	Moderate	6	30%	4	20%	10	50%	2.626	0.040*		
	Severe	1	5%	4	20%	5	25%				
Control	Mild	10	50%	3	15%	13	65%	2.842	0.077		
Control	Moderate	0	0%	7	35%	7	35%	2.042	0.077		

There is significant difference between male and female patients in anxiety as female patients show anxiety more than males in asthma [with P-value=0.045] and in patients on regular hemodialysis [with P-value=0.040].





Table 20: Comparison of depression between patients and control groups in different chronic diseases as regard to sex.

			Sex								
Groups	Depression	N	Male	Fe	emale	T	`otal	Chi	i-square		
		N	%	N	%	N	%	X^2	P-value		
	No	8	40%	5	25%	13	65%				
Asthma	Mild	1	5%	4	20%	5	25%	1.532	0.468		
	Moderate	0	0%	2	10%	2	10%				
	No	10	50%	5	25%	15	75%				
Diabetes	Mild	0	0%	3	15%	3	15%	1.501	0.247		
	Moderate	1	5%	1	5%	2	10%				
	No	3	15%	1	5%	4	20%				
	Mild	8	40%	3	15%	11	55%				
Renal	Moderate	0	0%	3	15%	3	15%	2.600	0.031*		
	Severe	0	0%	2	10%	2	10%				
	No	10	50%	8	40%	18	90%				
Control	Mild	0	0%	2	10%	2	10%	1.485	0.267		

There is significant difference between male and female patients in depression as female patients on regular hemodialysis show depression more than males [P-value=0.031].





Table 21: Comparison of anxiety between patients as a whole and control group as regard to sex

		Sex								
Groups	Anxiety]	Male	F	emale	7	Γotal	Chi-square		
		N	%	N	%	N	%	\mathbf{X}^2	P-value	
	Mild	18	30%	4	6.6%	22	36.7%			
Patients	Moderate	13	21.7%	15	25%	28	46.7%			
	Severe	1	1.6%	9	15%	10	16.6%	4.327	0.026*	
C41	Mild	10	50%	3	15%	13	65%			
Control	Moderate	0	0%	7	35%	7	35%			

There is significant increase in anxiety between the chronic diseased patients than healthy children as healthy children show no severe anxiety while 10(16.6%) of chronic diseased patients have severe anxiety.

Table 22: Effect of age of patients on anxiety between different diseases and control groups.

				A	Age			ΔN	OVA
Age	Anxiety	Range		Mean	±	SD	f	P-value	
	Mild	5	-	7	6.250	±	0.886		
Asthma	Moderate	7	-	10	8.700	±	1.160	25.312	<0.001*
	Severe	11	-	12	11.500	±	0.707		
	Mild	5	-	16	10.778	±	3.898		
Diabetes	Moderate	6	-	14	10.625	±	3.292	0.262	0.772
	Severe	9	-	16	12.333	±	3.512		
	Mild	8	-	17	13.800	±	3.768		
Renal	Moderate	12	-	17	14.800	±	1.549	0.234	0.794
	Severe	9	-	17	14.600	±	3.362		
Control	Mild	5	-	16	9.615	±	3.641	3.736	0.069
	Moderate	9	-	17	12.714	±	2.928	3.730	0.009

This table shows high significant increase in anxiety with aging of asthmatic patients with P-value<0.001






Fig. (6): Anxiety increases with age in asthmatic patients.

Table23: Effect of age of patients on depression between different diseases and control groups.

A ~~	Donmaggion	Г) on co		Mean		SD	AN	OVA
Age	Depression	Range			Mean	±	SD	f	P-value
	Mild	5	-	9	6.846	±	1.144	26.688	
Asthma	Moderate	9	-	10	9.600	±	0.548	20.000	<0.001*
	Severe	11	-	12	11.500	±	0.707		
	Mild	5	-	15	10.067	±	3.262	2.346	0.126
Diabetes	Moderate	9	-	16	13.000	±	3.606	2.340	0.120
	Severe	13	-	16	14.500	±	2.121		
	No	14	-	16	14.750	±	0.957		
Renal	Mild	8	-	17	13.727	±	3.165	2.639	0.028*
Kenai	Moderate	16	-	17	16.333	±	0.577	2.039	0.028
	Severe	14	-	17	15.500	±	2.121		
Control	Mild	5	-	16	10.444	±	3.518	0.873	0.363
Control	Moderate	9	-	17	13	±	5.657		

The table shows highly significant increase in depression with age increase between asthmatic patients with P-value<0.001 and significant increase in depression in patients on regular hemodialysis with P-value=0.028.





Table 24: Effect of disease complications on anxiety.

					Coi	mpli	cations			
Groups	Anxiety	(-ve)	(+	ve)	Γ	otal	Ch	i-square	
		N	%	N	%	N	%	X^2	P-value	
Asthma	Mild	8	40%	0	0%	8	40%			
	Moderate	10	50%	0	0%	10	50%	20.253	<0.001*	
	Severe	0	0%	2	10%	2	10%			
	Mild	5	25%	4	20%	9	45%		0.050*	
Diabetes	Moderate	4	20%	4	20%	8	40%	1.869		
	Severe	1	5%	2	10%	3	15%			
	Mild	1	5%	4	20%	5	25%			
Renal	Moderate	0	0%	10	50%	10	50%	2.639	0.049*	
	Severe	1	5%	4	20%	5	25%			

Highly significant increase in anxiety scores [P-value<0.001] in severely diseased asthmatic patients, and significant increase in anxiety with increased complications of diabetes [P-value=0.050] and in ESRD [P-value=0.049].





Table25: Effect disease complications on depression.

			Complications									
Groups	Depression	(-ve)		((+ve)		otal	Chi-square				
		N	%	N	%	N	%	\mathbf{X}^2	P-value			
A . (1	No	13	65%	0	0%	13	65%					
Asthma	Mild	5	25%	0	0%	5	25%	15.361	0.002*			
	Moderate	0	0%	2	10%	2	10%					
D' 1	No	9	45%	6	30%	15	75%	2.022	0.221			
Diabetes	Mild	1	5%	2	10%	3	15%	2.933	0.231			
	Moderate	0	0%	2	10%	2	10%					
	No	0	0%	4	20%	4	20%					
Renal	Mild	1	5%	10	50%	11	55%	2.996	0.030*			
	Moderate	1	5%	2	10%	3	15%					
	Severe	0	0%	2	10%	2	10%					

Significant increase in depression scores [P-value=0.002] in asthmatic patients with complications and with increased severity of renal failure [P-value=0.030].

Table 26: Effect of disease duration on anxiety and depression

	Duration								
	<1 year	>1year	T-test						
	Mean ± SD	Mean ± SD	T	P-value					
Anxiety	11 ± 2.449	23.736 ± 5.812	-5.697	<0.001*					
Depression	7.857 ± 6.094	10.170 ± 5.680	-2.205	0.032*					

This table shows high significant increase in anxiety scores with long duration of the disease [P-value<0.001] and significant increase in depression scores with P-value =0.032



Table 27: Effect of compliance to treatment between patients on anxiety and depression

	Compliance								
	Negative	Positive	T-test						
	Mean ± SD	Mean ± SD	T P-value						
Anxiety	32.889 ± 2.759	20.373 ± 5.542	6.598 <0.001*						
Depression	17.889 ± 4.833	8.490 ± 4.628	5.583 <0.001*						

This table shows high significant increase in anxiety scores [P-value<0.001] and depression scores [P-value<0.001] among non-compliant patients.




Fig.(7): Difference between compliant and non-compliant patients developing anxiety and depression.





Table 28: Relation between anxiety and depression in patients of different chronic diseases.

Crowns	Anxiety				Depression	1		Chi-square		
Groups	Alixiet	y	No	Mild	Moderate	Severe	Total	² X	P-value	
	Mild	N	8	0	0	0	8			
	MIII	%	40%	0%	0%	0%	40%		<0.001*	
A athma	Moderate	N	5	5	0	0	10	26.154		
Asthma	Moderate	%	25%	25%	0%	0%	50%	20.134		
	Cayara	N	0	0	2	0	2			
	Severe	%	0%	0%	10%	0%	10%			
	Mild	N	8	1	0	0	9		0.366	
		%	40%	5%	0%	0%	45%			
Diabetes	Moderate	N	6	1	1	0	8	4.306		
Diabetes		%	30%	5%	5%	0%	40%			
	Severe	N	1	1	1	0	3			
	Severe	%	5%	5%	5%	0%	15%			
	Mild	N	1	4	0	0	5			
	MIII	%	5%	20%	0%	0%	25%			
Renal	Moderate	N	3	6	1	0	10	12 063	0.050*	
Kellal	Moderate	%	15%	30%	5%	0%	50%	12.963	0.050*	
	Severe	N	0	1	2	2	5			
		%	0%	5%	10%	10%	25%			

This table shows highly significant relation between anxiety and depression grades in asthmatic patients with P-value<0.001 and significant relation between anxiety and depression in patients on regular hemodialysis with P-value=0.050.

Table 29: Comparison of PCS scores between patients in different chronic diseases.

		ANOVA		
	Range	Mean ± SD	f	P-value
Asthma	23.4 - 54.8	37.625 ± 11.001		
Diabetes	27.0 - 52.4	41.490 ± 7.999	5.741	0.005*
Renal	23.4 - 52.4	32.381 ± 5.786		

Significant difference between the three groups as regard PCS with P-value 0.005 with the lowest PCS scores in patients on regular haemodialysis.






Fig. (8): Quality of Life (PCS) scores in different chronic diseases.

Table 30: Comparison of MCS scores between patients in different chronic diseases.

		ANOVA		
	Range	Mean ± SD	f	P-value
Asthma	21.3 - 62.2	49.170 ± 13.489		
Diabetes	26.4 - 60.8	46.530 ± 10.326	15.352	<0.001*
Renal	19.3 - 53.1	31.635 ± 7.796		

Highly significant difference between the groups as regard MCS with P-value <0.001 with the lowest MCS scores are in patients on regular haemodialysis.






Fig. (9): Quality of Life (MCS) scores in different chronic diseases.

Table 31: Comparison of Quality of Life (PCS and MCS) between the different chronic diseased patients and control [as a whole] then individual comparison with [each other]:

marriada comparison with each other].										
		D	Range			±	SD	ANOVA		
		Range			Mean	I	SD	F	P-value	
	Asthma	23.4	-	54.8	37.625	±	11.001		<0.001*	
PCS	Diabetes	27	-	52.4	41.490	±	7.999	12 110		
PCS	Renal	23.7	-	41	32.381	±	5.786	42.448		
	Control	55	-	61.5	57.525	±	1.758			
P1		0.001*								
P2		0.002*								
P3					0.001*					
	Asthma	21.3	-	62.2	49.170	±	13.489			
MCS	Diabetes	26.4	-	60.8	46.530	±	10.326	17.246	<0.001*	
MCS	Renal	19.3	-	53.1	31.635	±	7.796	17.240	<0.001*	
	Control	40.4	-	60.8	52.580	±	6.798			
P1					0.051					
P2	0.022*									
P3					0.001*					

P1comparison between asthma & control P2comparison between diabetes & control P3comparison between renal & control





There is high significant decrease among patients in comparison to controls as regard to PCS and MCS (P-value<0.001). Individually, there is significant difference between all groups with control group in PCS and in MCS all groups except asthmatic patients.

Table 32: Scoring of anxiety, depression, PCS and MCS in patients of different chronic diseases within their disease duration.

		Range		Maan		CD	ANOVA		
		ľ	Cange	•	Mean	±	SD	f	P-value
	Asthma	13	-	34	25.55	±	4.568		
Anxiety	Diabetes	7	-	39	21.45	±	8.159	2.639	0.042*
Allxiety	Renal	9	-	34	22.75	±	6.965	2.039	0.042**
	Control	10	-	27	19.40	±	5.041		
Depression	Asthma	1	-	18	8.45	±	5.114		
	Diabetes	1	-	18	7.60	±	5.205	9.956	<0.001*
	Renal	5	-	24	13.65	±	5.092	9.930	
	Control	1	-	14	5.80	±	3.473		
	Asthma	23.4	-	54.8	37.625	±	11.001		
PCS	Diabetes	27	-	52.4	41.490	±	7.999	42.448	<0.001*
PCS	Renal	23.7	-	41	32.381	±	5.786	42.440	<0.001*
	Control	55	-	61.5	57.525	±	1.758		
	Asthma	21.3	-	62.2	49.170	±	13.489		
MCS	Diabetes	26.4	-	60.8	46.530	±	10.326	17.246	<0.001*
MCS	Renal	19.3	-	53.1	31.635	±	7.796	17.240	<0.001
	Control	40.4	-	60.8	52.580	±	6.798		
	Asthma	3	-	9	6.025	±	1.352		
Duration	Diabetes	1	-	8	3.875	±	2.089	8.399	<0.001*
Duration	Renal	1	-	8	4	±	2.052	0.399	<0.001*
	Control	0	-	0	0	±	0		

This table shows summary of psychiatric disorders (anxiety, depression) and Short Form-12 scoring through PCS and MCS within the duration of suffering from the different diseases, also in comparison with control group. There is significant difference between the four groups in depression, PCS, MCS and also their disease duration.






Fig. (10): Depression in different chronic diseases and control groups.




Fig. (11): PCS in different chronic diseases and control groups.






Fig. (12): MCS in different chronic diseases and control groups.

Table 33: Comparison of Quality of Life scores (PCS=Physical component summary and MCS=Mental component summary) between different groups as regard to sex.

		Sex							
		Male	Female	T-test					
		Mean ± SD	Mean ± SD	t P-value					
	Asthma	35.717 ± 10.733	40.488 ± 11.482	0.948 0.356					
PCS	Diabetes	42.047 ± 7.258	39.820 ± 10.720	4.325 0.022*					
PCS	Renal	33.792 ± 5.756	29.759 ± 5.237	3.258 0.039*					
	Control	57.188 ± 1.518	57.750 ± 1.932	0.691 0.498					
	Asthma	44.125 ± 14.277	56.738 ± 8.030	2.259 0.037*					
MCS	Diabetes	47.267 ± 9.769	44.320 ± 12.817	2.114 0.049*					
MCS	Renal	30.969 ± 8.675	32.871 ± 6.260	1.852 0.050*					
	Control	55.088 ± 5.838	50.908 ± 7.107	1.378 0.185					

There is significant difference between male and female patients (with lower scores in females=lower QOL) as regard to PCS in diabetic and patients on regular hemodialysis and as regard to MCS in patients of different chronic diseases.



Table 34: Effect of disease complications on quality of life scores.

		Complications									
	Groups	(-ve)	(+ve)	T-test							
		Mean ± SD	Mean ± SD	T P-value							
	Asthma	39.122 ± 10.557	24.150 ± 1.061	5.365 0.001*							
PCS	Diabetes	44.060 ± 7.705	38.920 ± 7.812	2.963 0.019*							
	Renal	26.950 ± 0.212	32.984 ± 5.793	2.107 0.024*							
	Asthma	51.994 ± 10.871	23.750 ± 3.465	3.576 0.002*							
MCS	Diabetes	47.710 ± 9.629	45.350 ± 11.370	0.501 0.623							
	Renal	28.300 ± 0.141	32.006 ± 8.153	2.582 0.041*							

There is significant decrease in PCS scores in different chronic diseases and in MCS in asthmatic and chronic renal patients with complications than those without complications.

Table 35:Correlation between age and Quality of Life scores of the patients then duration with QOL scores.

	Groups	P	CS	N	ICS
	Groups r		P-value	r	P-value
Age	Asthma	-0.752	<0.001*	-0.527	0.017*
	Diabetes	0.331	0.154	-0.196	0.408
	Renal	-0.481	0.032*	-0.082	0.044*
	Asthma	-0.463	0.027*	-0.398	0.019*
Duration	Diabetes	0.348	0.133	0.232	0.324
	Renal	-0.159	0.502	0.023	0.923

This table shows significant negative correlation between age and quality of life scores (PCS and MCS) between asthmatic and chronic renal patients. According to the duration, there is significant negative correlation between duration, PCS and MCS scores in between asthmatic patients.






Fig. (13): Negative correlation between PCS and age in asthmatic patients.




Fig. (14): Negative correlation between MCS and age of asthmatic patients.








Fig. (15): Negative correlation between PCS and asthma duration.




Fig. (16): Negative correlation between MCS and asthma duration.








Fig. (17): Negative correlation between PCS and age in patients on regular hemodialysis.

Table 36: Relation between anxiety and PCS scores.

Tuble 500 Relation between animoty and 1 eb bediese										
PCS	Anxiety	Range			Mean	+	SD	ANOVA		
res	Allxlety	Kange		ge .	Mean	Ι.	SD	f	P-value	
A a41a.aa -	Mild	33.60	-	54.80	47.725	±	7.050	15.044		
Asthma	Moderate	26.20	-	44.30	32.240	±	7.311	13.044	<0.001*	
	Severe	23.40	-	24.90	24.150	±	1.061			
Diabetes	Mild	27	-	52.40	44.900	±	7.823	1 646	0.222	
	Moderate	29.10	-	51.70	39.188	±	8.331	1.646	0.222	
	Severe	33.70	-	42.60	37.400	±	4.636			
Renal	Mild	23.70	-	41	32.460	±	7.731			
Reliai	Moderate	25.60	-	39.50	31.801	±	5.013	4.528	0.022*	
	Severe	26.80	-	40.90	33.460	±	6.357			
Control	Mild	55.00	-	61.50	57.738	±	1.869	0.534	0.474	
	Moderate	55.30	-	60	57.129	±	1.585			

This table shows highly significant relation between anxiety scores and mean values of PCS scores in between asthmatic patients with P-value <0.001 and significant relation in patients on regular hemodialysis with P-value=0.022. Lower PCS scores are associated with higher anxiety scores.





Table 37: Relation between anxiety and MCS scores.

MCS	Anvioty	Danga	Mean ±	CD	ANOVA	
MCS	Anxiety	Range	Mean ±	SD	f	P-value
Asthma	Mild	42.50 - 62.10	56.675 ±	7.079	8.729	0.002*
	Moderate	27.10 - 62.20	48.250 ±	12.214	8.729	0.002**
	Severe	21.30 - 26.20	23.750 ±	3.465		
Diabetes	Mild	48.50 - 60.80	54.178 ±	5.044	17 650	
Diabetes	Moderate	31.50 - 53.70	44.013 ±	7.833	17.652	<0.001*
	Severe	26.40 - 33.40	30.300 ±	3.568		
Renal	Mild	28.30 - 45.50	34.480 ±	7.711		
	Moderate	21.60 - 53.10	31.340 ±	8.564	2.638	0.028*
	Severe	19.30 - 36.80	29.380 ±	6.891		

This table shows highly significant relation between anxiety scores and mean values of MCS scores in diabetic patients with P-value <0.001 and significant difference in asthmatic patients [P-value=0.002] and ESRD patients [P-value=0.028]. Lower MCS scores are associated with higher anxiety scores.



Table 38: Relation between depression and PCS scores.

		Range			Mean	±	SD	AN	OVA
PCS	Depression							f	P-
									value
A athma	No	26.20	-	54.80	42.031	±	10.458	4.530	
Asthma	Mild	27.70	-	43.60	31.560	±	6.827	4.330	0.026*
	Moderate	23.40	-	24.90	24.150	±	1.061		
Diabetes	No	27	-	52.40	42.627	±	8.069	0.713	0.504
Diabetes	Mild	33.70	-	48.30	39.567	±	7.711	0.713	0.304
	Moderate	29.10	-	42.60	35.850	±	9.546		
	No	26.90	-	35.30	31.100	±	5.940		
Renal	Mild	26.80	-	40.90	33.400	±	7.093	2.253	0.042*
	Moderate	25.60	-	41	33.655	±	6.027	2.233	0.042
	Severe	23.70	-	33.90	28.750	±	4.473		
Control	No	55	-	61.50	57.644	±	1.774	0.824	0.376
	Mild	55.30	-	57.60	56.450	±	1.626		

This table shows significant relation between depression scores and mean values of PCS scores in between asthmatic [P-value=0.026] and ESRD patients [P-value=0.042]. Lower PCS scores are associated with higher depression scores.




Fig. (18): Relation between PCS and depression in asthmatic patients.




Table 39: Relation between depression and MCS scores.

					±	SD	ANG	OVA	
MCS	Depression	Range					Mean	f	P-
								1	value
Asthma	No	37.50	-	62.10	53.054	±	9.314	6.427	0.008*
Asuma	Mild	27.10	-	62.20	49.240	±	15.128	0.427	0.008
	Moderate	21.30	-	26.20	23.750	±	3.465		
Diabetes	No	33.40	-	60.80	50.500	±	7.289	8.515	0.003*
Diabetes	Mild	31.10	-	50.30	37.633	±	10.971	0.313	0.003
	Moderate	26.40	-	33.80	30.100	±	5.233		
	No	29	-	53.10	39.500	±	11.748		
Renal	Mild	21.60	-	39.60	30.082	±	4.668	2.996	0.049*
	Moderate	24.70	-	34.80	29.233	±	5.129		
	Severe	19.30	-	36.80	28.050	±	12.374		
Control	No	40.40	-	60.80	53.539	±	6.400	4.181	0.056
	Mild	41.10	-	46.80	43.950	±	4.031		

This table shows significant relation between depression scores and mean values of MCS scores in between different chronic patients [P-value =0.008 in asthma, =0.003 in diabetes, =0.049 inESRD]. Lower MCS scores are associated with higher depression scores.




Fig. (19): Relation between MCS and depression in asthmatic patients.






Fig. (20): Relation between MCS and depression in diabetic patients.

Table 40: Incidence of other psychological morbidities in the studied cases.

	Asthma		Dia	abetes	R	enal	Chi-square	
	N	%	N	%	N	%	\mathbf{X}^2	P-value
Low self esteem	5	25	5	25	11	55	6.328	0.028*
Social isolation	5	25	6	30	4	20	0.533	0.766
Aggression	2	10	2	10	1	5	0.436	0.804
Sleep disorders	8	40	6	30	14	70	6.964	0.031*
Thinking of Suicide	0	0	1	5	4	20	5.993	0.049*

Patients on regular hemodialysis have the upper hand in suffering from low self esteem in 11 patients (55%), sleep disorders with significant difference in 14 patients (70%) and thinking of suicide in 4 patients (20%) with significant difference from other diseases, social isolation in 4(20%) patients and aggression in 1(5%)patient.





In diabetes, low self esteem in 5(25%) patients, sleep disorders in 6(30%) patients, social isolation in 6(30%) patients, aggression in 2(10%) patients and thinking of suicide in one patient.

In asthma, low self esteem in 5(25%) patients, sleep disorders in 8(40%) patients, social isolation in 5(25%) patients and aggression in 2(10%) patients.